Evidence map›Paper›PMID 36378996›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules.

Huixiong Xu, Yifeng Zhang, Hongxun Wu, Ning Zhou, Xing Li, John P Pineda, Yun Zhu, Huijun Fu, Ming Ying, Shufang Yang and 20 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05707585 (A Multicenter Study for Evaluating the Benign and Malignant Pulmonary Noldules by Detecting the Epigenetic Imprinting Alterations in Bronchoalveolar Lavage), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05707585 unknown statusnot on this map

A Multicenter Study for Evaluating the Benign and Malignant Pulmonary Noldules by Detecting the Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

TypeobservationalSponsorThe Second Affiliated Hospital of Dalian Medical UniversityRan2023 to 2024Enrolled2,064ConditionsLung CancerArmsQuantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. PHLDA2 in cancer: From molecular mechanisms to therapeutic opportunities.The Journal of pharmacology and experimental therapeutics · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 7 institutions in 1 country.

Huixiong XuDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
Yifeng ZhangDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
Hongxun WuDepartments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.ORCID 0000-0003-2837-2458
Ning ZhouLisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
Xing LiLisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
John P PinedaLisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
Yun ZhuDepartments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
Huijun FuThe Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Ming YingDepartments of Ultrasound and Endocrinology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Shufang YangDepartments of Ultrasound and Endocrinology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Jiandong BaoDepartments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
Lulu YangDepartment of Pathology, Nanjing First Hospital, Nanjing, Jiangsu, China.
Bingjie ZhangDepartments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
Lehang GuoDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
Liping SunDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
Feng LuDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
Hanxiang WangDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
Ying HuangDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Tiantong ZhuDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaonan WangLisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
Qing WeiThe Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Chunjun ShengThe Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Shen QuThe Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhongwei LvThe Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Dong XuDepartment of Ultrasound, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID 0000-0002-0583-240X
Qian LiDepartment of Ultrasound, Henan Cancer Hospital, Zhengzhou, Henan, China.
Yongling DongDepartment of Ultrasound, Henan Cancer Hospital, Zhengzhou, Henan, China.
Jianwu QinDepartment of Thyroid and Breast Surgery, Henan Cancer Hospital, Zhengzhou, Henan, China.
Tong ChengLisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
Mingzhao XingSchool of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.ORCID 0000-0003-4797-610X
Tongji University · CNHenan Cancer Hospital · CNChina Medical University · CNNantong University · CNCancer Hospital of Chinese Academy of Medical Sciences · CNNanjing Medical University · CNSouthern University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo explore the novel diagnostic value of epigenetic imprinting biomarkers in thyroid nodules. PATIENTS AND

methodsA total of 550 patients with fine-needle aspiration (FNA)-evaluated and histopathologically confirmed thyroid nodules were consecutively recruited from eight medical centers. Quantitative chromogenic imprinted gene in situ hybridization (QCIGISH) was used to assess the allelic expression of imprinted genes

resultsFor thyroid malignancy, the QCIGISH test achieved an overall diagnostic sensitivity of 100% (277/277), a specificity of 91.5% (107/117; 95% CI, 86.4 to 96.5), a positive predictive value (PPV) of 96.5% (95% CI, 94.4 to 98.6), and a negative predictive value (NPV) of 100% in the prospective validation, with a diagnostic accuracy of 97.5% (384/394; 95% CI, 95.9 to 99.0). QCIGISH demonstrated a PPV of 97.8% (95% CI, 94.7 to 100) and NPV of 100%, with a diagnostic accuracy of 98.2% (111/113; 95% CI, 95.8 to 100), for indeterminate Bethesda III-V thyroid nodules. QCIGISH demonstrated a PPV of 96.6% (95% CI, 91.9 to 100) and a NPV of 100%, with a diagnostic accuracy of 97.5% (79/81; 95% CI, 94.2 to 100), for Bethesda III-IV. For Bethesda VI, QCIGISH showed a 100% (184/184) accuracy.

conclusionThis imprinting biomarker-based test can effectively distinguish malignant from benign thyroid nodules. The high PPV and NPV make the test both an excellent rule-in and rule-out diagnostic tool. With such a diagnostic performance and its technical simplicity, this novel thyroid molecular test is clinically widely applicable.

Indexed as

Thyroid NeoplasmsThyroid NoduleBiomarkersEpigenesis, GeneticHumansRetrospective StudiesBiomarkers

Identifiers

PMID36378996
PMCPMC9937101
OpenAlexW4309161329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.